NCT03003637View on ClinicalTrials.gov

ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

February 28, 2017

Primary Completion Date

October 12, 2019

Study Completion Date

February 12, 2021

Conditions
ImmunotherapyHead and Neck Neoplasms
Interventions
DRUG

Nivolumab

Nivolumab (240 mg flat dose, week 1 and week 3, twice in total) monotherapy, neoadjuvant to SOC (surgery with or without adjuvant (C)RT).

DRUG

Ipilimumab

Ipilimumab (1 mg/kg) only in week 1, in combination with nivolumab (240 mg flat dose, week 1 and week 3, twice in total), neoadjuvant to SOC (surgery with or without adjuvant (C)RT).

Trial Locations (1)

1066CX

NKI-AVL, Amsterdam

All Listed Sponsors
lead

The Netherlands Cancer Institute

OTHER

NCT03003637 - ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma | Biotech Hunter | Biotech Hunter